BioSpace News Archive

Leidos, a FORTUNE® 500 science and technology leader, was recently awarded a new prime contract to provide biomedical preclinical and development capabilities to support the National Institute of Allergy and Infectious Diseases.

Swedish Orphan Biovitrum AB and Sanofi announced positive top-line results from the pivotal XTEND-1 phase 3 study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa in previously treated patients ≥12 years of age with severe haemophilia A.

OSE Immunotherapeutics, announced that early biomarker analyses from the ongoing Phase 1 clinical trial with SIRPα inhibitor BI 765063 in patients with advanced solid tumors have been selected for presentation in an in-person poster session at the American Association Cancer for Research annual meeting to be held on April 8 – 13, 2022 in New Orleans, Louisiana.

Nordic Nanovector ASA announces that an E-poster regarding Alpha37, entitled “Targeted alpha therapy with 212Pb-NNV003 in treatment of NHL”, will be presented at the 2022 American Association of Cancer Research Annual Meeting held 8-13 April in New Orleans, USA.

iOnctura SA will present preclinical data on its next-generation autotaxin inhibitor, IOA-289, at the annual meeting of the American Association for Cancer Research taking place on April 8-13, 2022 in New Orleans, Louisiana.

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer will be presenting a poster with new and promising preliminary Phase I data on TG4050, its individualized neoantigen cancer vaccine, at the AACR Annual Meeting 2022.

Transgene and BioInvent International AB jointly announce that an abstract reporting preclinical studies of BT-001, a novel oncolytic virus, has been selected for a poster presentation at the American Association for Cancer Research Annual Meeting 2022.

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced key strategic and operational results for the year ended December 31, 2021.

Sirona Biochem Corp. is pleased to announce that its wholly owned subsidiary TFChem, has been awarded financing to develop an advanced chemistry process that could improve the manufacturing of active ingredients.

Ultivue, Inc. and Aignostics GmbH announced a partnership to collaborate on the co-development of AI-powered spatial multiplexed immunophenotype solutions for translational research groups and Biopharma.